An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization:3-year clinical outcomes of a randomized non-inferiority trial

Autor: Xiao-Ping Zhang, Lu Shoutao, Haijun Zhang, Wei Deng, Duan Cuihai, Fei Yang, Junbo Ge, Hou Wenbo, Chao Zhou, Yin Yuxia, Shenguo Wang, Cui Xiaoshan, Liu Guang, Song Caixia, Zhang Junwei

Publikováno v: Zhang, H, Zhang, X, Yin, Y, Zhou, C, Deng, W, Zhang, J, Hou, W, Lu, S, Song, C, Cui, X, Wang, S, Yang, F, Liu, G, Duan, C & Ge, J 2019, ' An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization : 3-year clinical outcomes of a randomized non-inferiority trial ', Scientific Reports, vol. 9, no. 1, 18549 . https://doi.org/10.1038/s41598-019-54964-8
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)

The Cordimax stent has proved non-inferior to the Cypher Select durable polymer sirolimus-eluting stent for the primary endpoint of angiographic in-stent late luminal loss and in-stent mean diameter stenosis at 9 months. The trial was designed to com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a65fdb51fe9ebc5c81f2b0617655cb25
https://vbn.aau.dk/da/publications/f5b70457-c6c9-4421-8a92-4fa8f55309f8

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

Autor: Michael Platten, G. Pesce, Thierry Gorlia, Kirsten Hopkins, Vassilis Golfinopoulos, Markus Kosch, Wolfgang Wick, Jean-Sebastien Frenel, Christine Marosi, Jonathan Steuve, Michael Weller, Mario Campone, Martin J. van den Bent, Antje Wick, Benoit Lhermitte, Salvador Villà, Krisztian Homicsko, Astrid Weyerbrock, Monika E. Hegi, Pierre Bady, Marie-France Hamou, Damien Ricard, Patrick Roth, Alba A. Brandes, Martin J.B. Taphoorn, Roger Stupp

Publikováno v: Clinical Cancer Research, 22(19), 4797-4806. American Association for Cancer Research Inc.
Clinical Cancer Research, 22(19), 4797-4806
Clinical Cancer Research
Clinical cancer research, vol. 22, no. 19, pp. 4797-4806

Purpose: EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA-methyltransferase (MGMT) promoter. Experimental Design: Patients (n = 257) fulfilling eligibility

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9d7fef0d1608d3697456d8fd4775b80
https://doi.org/10.1158/1078-0432.ccr-15-3153

The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis):Angiographic Results and 1-Year Clinical Outcomes

Autor: Verheye, Stefan, Vrolix, Mathias, Kumsars, Indulis, Erglis, Andrejs, Sondore, Dace, Agostoni, Pierfrancesco, Cornelis, Kristoff, Janssens, Luc P F, Maeng, Michael, Slagboom, Ton, Amoroso, Giovanni, Jensen, Lisette Okkels, Granada, Juan F, Stella, Pieter

Publikováno v: Verheye, S, Vrolix, M, Kumsars, I, Erglis, A, Sondore, D, Agostoni, P, Cornelis, K, Janssens, L, Maeng, M, Slagboom, T, Amoroso, G, Jensen, L O, Granada, J F & Stella, P 2017, ' The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis) : Angiographic Results and 1-Year Clinical Outcomes ', JACC. Cardiovascular interventions, vol. 10, no. 20, pp. 2029-2037 . https://doi.org/10.1016/j.jcin.2017.06.021
Verheye, S, Vrolix, M, Kumsars, I, Erglis, A, Sondore, D, Agostoni, P, Cornelis, K, Janssens, L, Maeng, M, Slagboom, T, Amoroso, G, Jensen, L O, Granada, J F & Stella, P 2017, ' The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis) Angiographic Results and 1-Year Clinical Outcomes ', J A C C: Cardiovascular Interventions, vol. 10, no. 20, pp. 2029-2037 . https://doi.org/10.1016/j.jcin.2017.06.021
JACC. Cardiovascular Interventions, 10(20), 2029. Elsevier Inc.

OBJECTIVES The aim of this first-in-human study was to assess the safety and effectiveness of the Virtue sirolimus-eluting balloon in a cohort of patients with in-stent restenosis (ISR). BACKGROUND Angioplasty balloons coated with the cytotoxic drug

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0ada97350efff65e1c1b831c51fb91d1
https://pure.au.dk/portal/da/publications/the-sabre-trial-sirolimus-angioplasty-balloon-forcoronary-instent-restenosis(ce661a2b-8cd9-44af-add9-d8aa8c89c5c0).html

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Autor: Edmond Chouinard, Michael Gnant, Janice F. Eakle, Alejandra T. Perez, Shinzaburo Noguchi, Martine Piccart, Wentao Feng, Gabriel N. Hortobagyi, Kathleen I. Pritchard, José Baselga, Puttisak Puttawibul, Mona El-Hashimy, Tetiana Taran, H. Bauly, Tibor Csoszi, Hope S. Rugo, Matthias Geberth, Vichien Srimuninnimit, Howard A. Burris

Publikováno v: Annals of oncology, 25 (4
Annals of oncology : official journal of the European Society for Medical Oncology, vol 25, iss 4
Annals of Oncology

Background: In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30bf62c296471f3511e5d07a084645fe
https://doi.org/10.1093/annonc/mdu009

Drug eluting stents for the treatment of bare metal in-stent restenosis: long-term outcomes in real world practice

Autor: Raj S. Khattar, Farzin Fath-Ordoubadi, Clare Appleby, Bernard Clarke, Ludwig Neyses, Nick Curzen, Kenneth P. Morgan

Publikováno v: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 6(6), 748-53. France (2011).

AIMS: Drug eluting stents (DES) have had a great impact in reducing in-stent restenosis (ISR) in de novo lesions. However, long-term data regarding effectiveness and safety of these stents in treating bare metal stent (BMS) ISR are limited. We report

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39e641a1dd15ebd8f79f4e1555c04da8
https://doi.org/10.4244/eijv6i6a127